<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aberrant DNA methylation (DNAm) is a feature of most types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Genome-wide DNAm profiling has been performed successfully on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue DNA samples </plain></SENT>
<SENT sid="2" pm="."><plain>However, the invasive procedure limits the utility of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue for epidemiological studies </plain></SENT>
<SENT sid="3" pm="."><plain>While recent data indicate that cell-free circulating DNAm (cfDNAm) profiles reflect DNAm status in corresponding <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues, no studies have examined the association of cfDNAm with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> or precursors on a genome-wide scale </plain></SENT>
<SENT sid="4" pm="."><plain>The objective of this pilot study was to evaluate the putative significance of genome-wide cfDNAm profiles in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EA) and <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> (BE, EA precursor) </plain></SENT>
<SENT sid="5" pm="."><plain>We performed genome-wide DNAm profiling in EA tissue DNA (n = 8) and matched serum DNA (n = 8), in serum DNA of BE (n = 10), and in healthy controls (n = 10) using the Infinium HumanMethylation27 BeadChip that covers 27,578 CpG loci in 14,495 genes </plain></SENT>
<SENT sid="6" pm="."><plain>We found that cfDNAm profiles were highly correlated to DNAm profiles in matched <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue DNA (r = 0.92) in patients with EA </plain></SENT>
<SENT sid="7" pm="."><plain>We selected the most differentially methylated loci to perform hierarchical clustering analysis </plain></SENT>
<SENT sid="8" pm="."><plain>We found that 911 loci can discriminate perfectly between EA and control samples, 554 loci can separate EA from BE samples, and 46 loci can distinguish BE from control samples </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that genome-wide cfDNAm profiles are highly consistent with DNAm profiles detected in corresponding <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="10" pm="."><plain>Differential cfDNAm profiling may be a useful approach for the noninvasive screening of EA and EA <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesions</z:e> </plain></SENT>
</text></document>